U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Previous Screen

Methotrexate Sodium Injection
Status: Currently in Shortage
»Date first posted: 03/13/2023
»Therapeutic Categories: Rheumatology; Oncology

Expand all

Accord Healthcare Inc. (Revised 02/05/2024)

Company Contact Information:
866-941-7875, option 2

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30) Unavailable, Next Delivery and Estimated Recovery TBD Inventory on hold pending further assessment. Requirements related to complying with good manufacturing practices
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35) Available Stock Available; Inventory allocating to orders

Fresenius Kabi USA, LLC (Reverified 02/01/2024)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50) Available Available. Check wholesaler for inventory
Injection, 25 mg/1 mL (NDC 63323-123-10) Available Available. Check wholesaler for inventory.

Hikma Pharmaceuticals USA, Inc. (Revised 02/22/2024)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methotrexate Injection, USP Preservative Free, Injection, 1 g (NDC 0143-9830-01) Available Currently available. Additional product will be made available as it is released.
Methotrexate Injection,USP Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10) Unavailable Additional lots will be available in the February 2024 timeframe. Product will be made available as it is released. Demand increase for the drug

Hospira, Inc., a Pfizer Company (Revised 02/09/2024)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methotrexate, Injection, 25 mg/1 mL (NDC 61703-350-38) Available

Pfizer Oncology Customer Letter (link)

Methotrexate, Injection, 25 mg/1 mL (NDC 61703-350-10) Available
Methotrexate, Injection, 25 mg/1 mL (NDC 61703-408-41) Available

Pfizer Oncology Customer Letter (link)

Methotrexate, Injection, 25 mg/1 mL (NDC 61703-408-25) Available
Methotrexate, Injection, 25 mg/1 mL (NDC 61703-124-40) Available

Teva Pharmaceuticals USA, Inc. (Revised 02/06/2024)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01) Available
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01) Available
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01) Available
Back to Top